Clinical trials: Leishmaniasis, Visceral
Visceral Leishmaniasis
Evaluation to Assess the Usability of rK28 for the Diagnosis of Visceral Leishmaniasis in Kenya
Visceral leishmaniasis (VL) is a fatal disease caused by Leishmania parasites and transmitted by female phlebotomine sandflies. The disease is a serious public health problem in eastern Africa; including Kenya where an estimated…
- Trial name
- rK28-AccDemo (NCT05386875)
- Testing
- rK28
- Where
- 4 sites in Kenya
- Volunteers
- 625 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Kinetoplastid, Skin Diseases, Parasitic
Diagnosis and Treatment of Leishmania Infections
Patients admitted on this protocol must have an active Leishmania infection. The major objectives of the protocol are to diagnose and classify the Leishmania infection and to provide species-based therapy to study the natural…
- Conditions
- Kinetoplastid, Skin Diseases, Parasitic, Parasitic Diseases, Leishmaniasis
- Trial name
- NCT00344188
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Visceral Leishmaniasis
Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure
Left untreated, visceral leishmaniasis (VL) is fatal. The highest burden of VL worldwide is in eastern Africa where field-adapted diagnostic and test-of-cure tools and treatment are lacking.
- Trial name
- VL-ToC (NCT05426577)
- Testing
- ELISA, LAMP, Cytokine Release Assay
- Where
- Ethiopia
- Volunteers
- 60 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Visceral Leishmaniasis
An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh
The purpose of this study is to evaluate the effectiveness of treatment with PMIM in patients with visceral leishmaniasis within the VL-endemic region of Bangladesh at EOT (21/22 days after treatment begins), and at 6 months…
- Trial name
- NCT01328457
- Testing
- Paromomycin sulfate
- Where
- 3 sites in Bangladesh
- Volunteers
- 120 people
- Sponsor
- PATH
Visceral Leishmaniasis
Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis
This modular Program will first confirm the safety and efficacy of Paromomycin IM Injection when given to an expanded population in the outpatient setting in experienced VL centers and subsequently evaluate the effectiveness of…
- Trial name
- NCT00604955
- Testing
- Paromomycin sulfate
- Where
- 7 sites in India
- Volunteers
- 2,000 people
- Sponsor
- PATH
Invasive Fungal Infections, Neutropenic Fever
Human Bioequivalence Study of Amphotericin B Liposome for Injection
Single-center, randomized, open-label, single-dose, two-treatment, two-period, two-sequence crossover design to evaluate the human bioequivalence of two Amphotericin B Liposome for Injection formulations
- Conditions
- Invasive Fungal Infections, Neutropenic Fever, Visceral Leishmaniasis
- Trial name
- NCT06977490
- Testing
- Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.), Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Visceral Leishmaniasis, Malnutrition
Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia
The project Visceral Leishmaniasis and Malnutrition is a cohort study that aimed to assess the association between malnutrition and visceral leishmaniasis (VL).
- Trial name
- VL&MNEthio (NCT02148822)
- Volunteers
- 520 people
- Sponsor
- Instituto de Salud Carlos III
Leishmaniasis
Mediterranean Visceral Leishmaniasis With Leishmania Infantum
L. infantum leishmaniasis is endemic in the South of France. For several years, there has been an expansion of the territory of sandflies (vector of leishmaniasis), with the appearance of cases of canine leishmaniasis in new…
- Trial name
- AsymptoGen (NCT03784248)
- Testing
- blood donation and isolation of leuco-platelet layers
- Where
- France
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Visceral Leishmaniasis, Chagas Disease
A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects
The purpose of this first-in-human study is to generate the necessary safety, tolerability, and pharmacokinetics (PK) information that will support further clinical development of LXE408 for the treatment of patients with…
- Trial name
- NCT07809919
- Testing
- LXE408, Iohexol
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Leishmania Infantum Disease, Leishmaniasis, Visceral
LEISH-PED: Study on Leishmaniasis in Children
Leishmaniasis is an infection caused by Leishmania parasites. In children, it can affect the skin or internal organs. Diagnosis may be delayed because the signs and symptoms can be similar to those of other conditions.
- Conditions
- Leishmania Infantum Disease, Leishmaniasis, Visceral, Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous
- Trial name
- LEISH-PED (NCT07504757)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Meyer Children's Hospital IRCCS
Visceral Leishmaniasis
Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers
The purpose of this study is to compare the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prevention of visceral leishmaniasis.
- Trial name
- NCT02071758
- Testing
- LEISH-F3 + SLA-SE, LEISH-F3 + GLA-SE
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Access to Advanced Health Institute (AAHI)
Visceral Leishmaniasis
A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
ImmStat@Cure is a multicentre observational study designed to assess the immune status of patients before and after treatment for visceral leishmaniasis. Forty patients and 30 controls will be recruited per site.
- Trial name
- NCT04342715
- Testing
- Sodium stibogluconate / paramomycin
- Where
- Kenya
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of York
Visceral Leishmaniasis, Cutaneous Leishmaniases
Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects
This study will evaluate how the test medicine DNDI-0690 is taken up and broken down by the body and will also look at the safety and tolerability of the test medicine after a single dose.
- Trial name
- NCT03929016
- Testing
- DNDI-0690
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Visceral Leishmaniasis
A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar
The purpose of this study is: 1. To evaluate the Safety and Efficacy of four different short-course regimens of Amphotericin B emulsion in treatment of Kala-azar (visceral leishmaniasis) subjects who are either treatment naive or…
- Trial name
- NCT00497601
- Testing
- Amphotericin B fat emulsion in visceral leishmaniasis, Amphotericin B fat emulsion, Amphotericin B in fat emulsion
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Banaras Hindu University
Visceral Leishmaniasis
Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children
The purpose of this study is to determine if amphotericin B is effective against visceral leishmaniasis in Brazilian children. Amphotericin B will be compared to meglumine antimoniate which is the current approved drug used for…
- Trial name
- LVTO (NCT01032187)
- Testing
- Meglumine antimoniate, Amphotericin B-deoxycholate
- Where
- 2 sites in Brazil
- Volunteers
- 101 people
- Sponsor
- University of Brasilia
Leishmaniasis, Leishmaniasis, Visceral
Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
This study aims to describe the burden of Post-Kala-Azar Dermal Leishmaniasis and visceral leishmaniasis relapse in a cohort of patients discharged after successful treatment of primary visceral leishmaniasis.
- Conditions
- Leishmaniasis, Leishmaniasis, Visceral, Post-kala-azar Dermal Leishmaniasis
- Trial name
- PKDL (NCT05449717)
- Where
- South Sudan
- Volunteers
- 52 people
- Sponsor
- Epicentre
Brucelloses, Epidemic Hemorrhagic Fever
Real World Study of Classic Infectious Disease
This study aimed to collect and analyze clinical specimens of patients with classic infectious diseases in the real world. To investigate the epidemiological distribution of classic infectious diseases (brucellosis, epidemic…
- Conditions
- Brucelloses, Epidemic Hemorrhagic Fever, Kala-Azar
- Trial name
- NCT04020536
- Testing
- Antibiotics
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Huashan Hospital
Visceral Leishmaniasis
Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis
The purpose of this trial is to evaluate the efficacy of single dose amphotericin B in the treatment of Visceral Leishmaniasis (VL) in India.
- Trial name
- NCT00628719
- Testing
- Liposomal Amphotericin B, amphotericin B deoxycholate
- Where
- India
- Volunteers
- 400 people
- Sponsor
- Banaras Hindu University
Kala Azar
Miltefosine for Brazilian Visceral Leishmaniasis
Miltefosine will be administered to Brazilian patients with kala azar
- Trial name
- NCT00378495
- Testing
- Miltefosine: initially 2.5 mg/kg/day for 28 days
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- AB Foundation
Visceral Leishmaniasis
An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis
It is a randomized, double-blind, multi-center, two-arm study intended to assess the safety and efficacy of three different doses/dose regimens of paromomycin administered intramuscularly as follows: 11 mg/kg/day for 14 days and…
- Trial name
- NCT00629031
- Testing
- Paromomycin
- Where
- India
- Volunteers
- 329 people
- Sponsor
- Banaras Hindu University